Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. more
Time Frame | ADXN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.88% | 0.31% | -1.26% |
1-Month Return | -5.86% | 0.6% | -4.16% |
3-Month Return | -29.62% | -9.44% | -0.46% |
6-Month Return | -11.18% | -5.15% | 3.58% |
1-Year Return | 5.92% | 0.33% | 22.47% |
3-Year Return | -93.81% | 4.53% | 25.13% |
5-Year Return | -97.45% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.76M | 3.61M | 2.92M | 1.42M | 1.61M | [{"date":"2019-12-31","value":76.47,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":80.72,"profit":true},{"date":"2022-12-31","value":39.37,"profit":true},{"date":"2023-12-31","value":44.65,"profit":true}] |
Cost of Revenue | 230.10K | 10.37M | 12.82M | 14.62M | 6.94M | [{"date":"2019-12-31","value":1.57,"profit":true},{"date":"2020-12-31","value":70.94,"profit":true},{"date":"2021-12-31","value":87.66,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.43,"profit":true}] |
Gross Profit | 2.53M | (6.76M) | (9.90M) | (13.20M) | (5.32M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-266.92,"profit":false},{"date":"2021-12-31","value":-390.97,"profit":false},{"date":"2022-12-31","value":-521.22,"profit":false},{"date":"2023-12-31","value":-210.15,"profit":false}] |
Gross Margin | 91.67% | (187.12%) | (339.55%) | (928.06%) | (329.99%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-204.12,"profit":false},{"date":"2021-12-31","value":-370.39,"profit":false},{"date":"2022-12-31","value":-1012.37,"profit":false},{"date":"2023-12-31","value":-359.97,"profit":false}] |
Operating Expenses | 17.37M | 15.86M | 18.42M | 21.94M | 11.89M | [{"date":"2019-12-31","value":79.15,"profit":true},{"date":"2020-12-31","value":72.26,"profit":true},{"date":"2021-12-31","value":83.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":54.21,"profit":true}] |
Operating Income | (14.83M) | (12.24M) | (15.51M) | (20.52M) | (10.28M) | [{"date":"2019-12-31","value":-1483430800,"profit":false},{"date":"2020-12-31","value":-1224327400,"profit":false},{"date":"2021-12-31","value":-1550591700,"profit":false},{"date":"2022-12-31","value":-2052020700,"profit":false},{"date":"2023-12-31","value":-1028129900,"profit":false}] |
Total Non-Operating Income/Expense | (37.94K) | (649.52K) | 96.31K | (303.65K) | (232.57K) | [{"date":"2019-12-31","value":-39.39,"profit":false},{"date":"2020-12-31","value":-674.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-315.28,"profit":false},{"date":"2023-12-31","value":-241.47,"profit":false}] |
Pre-Tax Income | (14.78M) | (12.86M) | (15.35M) | (20.80M) | (10.56M) | [{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}] |
Income Taxes | 128.52K | 207.76K | 116.38K | 123.91K | 21.61K | [{"date":"2019-12-31","value":61.86,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.01,"profit":true},{"date":"2022-12-31","value":59.64,"profit":true},{"date":"2023-12-31","value":10.4,"profit":true}] |
Income After Taxes | (14.91M) | (13.07M) | (15.47M) | (20.93M) | (10.58M) | [{"date":"2019-12-31","value":-1490912200,"profit":false},{"date":"2020-12-31","value":-1306636100,"profit":false},{"date":"2021-12-31","value":-1546829100,"profit":false},{"date":"2022-12-31","value":-2092812300,"profit":false},{"date":"2023-12-31","value":-1057783400,"profit":false}] |
Income From Continuous Operations | (14.78M) | (12.86M) | (15.35M) | (20.80M) | (10.56M) | [{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.78M) | (12.86M) | (15.35M) | (20.80M) | (10.56M) | [{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}] |
EPS (Diluted) | (0.62) | (0.87) | (2.99) | (3.57) | - | [{"date":"2019-12-31","value":-62.18,"profit":false},{"date":"2020-12-31","value":-87.3,"profit":false},{"date":"2021-12-31","value":-299,"profit":false},{"date":"2022-12-31","value":-357.36,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ADXN | |
---|---|
Cash Ratio | 3.78 |
Current Ratio | 4.59 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ADXN | |
---|---|
ROA (LTM) | -61.71% |
ROE (LTM) | -126.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ADXN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ADXN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 10.43 |
P/B | 0.66 |
Price/FCF | NM |
EV/R | 8.81 |
EV/Ebitda | NM |
Addex Therapeutics Ltd (ADXN) share price today is $7.39
Yes, Indians can buy shares of Addex Therapeutics Ltd (ADXN) on Vested. To buy Addex Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADXN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Addex Therapeutics Ltd (ADXN) via the Vested app. You can start investing in Addex Therapeutics Ltd (ADXN) with a minimum investment of $1.
You can invest in shares of Addex Therapeutics Ltd (ADXN) via Vested in three simple steps:
The 52-week high price of Addex Therapeutics Ltd (ADXN) is $27.9. The 52-week low price of Addex Therapeutics Ltd (ADXN) is $6.45.
The price-to-earnings (P/E) ratio of Addex Therapeutics Ltd (ADXN) is
The price-to-book (P/B) ratio of Addex Therapeutics Ltd (ADXN) is 0.66
The dividend yield of Addex Therapeutics Ltd (ADXN) is 0.00%
The market capitalization of Addex Therapeutics Ltd (ADXN) is $7.90M
The stock symbol (or ticker) of Addex Therapeutics Ltd is ADXN